Draft:Mind Medicine Australia
| Submission declined on 28 March 2024 by The Herald (talk). This submission reads more like an essay than an encyclopedia article. Submissions should summarise information in secondary, reliable sources and not contain opinions or original research. Please write about the topic from a neutral point of view in an encyclopedic manner. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 8 March 2024 by Drmies (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by Drmies 2 months ago.
| |
Comment: References (secondary sources) need to describe the actual subject of the article, not what they advocate. Drmies (talk) 04:12, 8 March 2024 (UTC)
Mind Medicine Australia is a not-for-profit organization based in Melbourne, Australia, dedicated to advancing psychedelic-assisted therapies for mental illness. Founded in 2019, the organization aims to alleviate the suffering caused by mental illness through the integration of psychedelic medicines into mainstream mental health care.
Overview[edit]
Mind Medicine Australia advocates for the therapeutic potential of psychedelic substances such as psilocybin, MDMA, and ketamine, based on evidence-based research..[1]. These substances have shown promise in clinical trials for various mental health conditions, including depression[2], post-traumatic stress disorder (PTSD)[3], anxiety disorders[4], and substance use disorders[5]
Activities[edit]
Mind Medicine Australia conducts educational programs, workshops, and conferences to raise awareness about the benefits of psychedelic-assisted therapies among the general public, healthcare professionals, and policymakers[6]. Additionally, the organization advocates for regulatory reforms to facilitate safe and legal access to these therapies for those in need.
One of the key initiatives of Mind Medicine Australia is the training of healthcare professionals in psychedelic-assisted therapy protocols[6]. The organization offers educational programs and certification courses for therapists, doctors, and other healthcare practitioners interested in incorporating psychedelic-assisted treatments into their clinical practice.
Furthermore, Mind Medicine Australia supports and funds research projects investigating the safety and efficacy of psychedelic-assisted therapies[6]. By contributing to the growing body of scientific evidence, the organization aims to build a strong case for the integration of these therapies into mainstream mental health care.
In February 2023, Mind Medicine Australia's rescheduling submission to the Therapeutic Goods Administration (TGA) led to the rescheduling of Psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder[7]. Since July 2023[8], Psychiatrists who are authorised prescribers have been able to prescribe these medicines in Australia[9]. Australia is the first country in the world to approve MDMA and psilocybin as an authorised medicine[10]
References[edit]
- ^ Carhart-Harris, Rl; Nutt, Dj (September 2017). "Serotonin and brain function: a tale of two receptors". Journal of Psychopharmacology. 31 (9): 1091–1120. doi:10.1177/0269881117725915. ISSN 0269-8811. PMC 5606297. PMID 28858536.
- ^ Palhano-Fontes, Fernanda; Barreto, Dayanna; Onias, Heloisa; Andrade, Katia C.; Novaes, Morgana M.; Pessoa, Jessica A.; Mota-Rolim, Sergio A.; Osório, Flávia L.; Sanches, Rafael; Santos, Rafael G. dos; Tófoli, Luís Fernando; Silveira, Gabriela de Oliveira; Yonamine, Mauricio; Riba, Jordi; Santos, Francisco R. (March 2019). "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial". Psychological Medicine. 49 (4): 655–663. doi:10.1017/S0033291718001356. ISSN 0033-2917. PMC 6378413. PMID 29903051.
- ^ Strassman, Ruck J.; Qualls, Clifford R.; Uhlenhuth, Eberhard H.; Kellner, Robert (1994-02-01). "Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale". Archives of General Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. ISSN 0003-990X. PMID 8297217.
- ^ Strassman, Ruck J.; Qualls, C. R.; Uhlenhuth, E. H.; Kellner, R. (1994). "Dose-Response Study of N,N-Dimethyltryptamine in Humans". Archives of General Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. PMID 8297217. Retrieved 2024-03-08.
- ^ Nutt, David J.; King, Leslie A.; Nichols, David E. (August 2013). "Effects of Schedule I drug laws on neuroscience research and treatment innovation". Nature Reviews Neuroscience. 14 (8): 577–585. doi:10.1038/nrn3530. ISSN 1471-0048. PMID 23756634. S2CID 1956833.
- ^ a b c "About Us · Mind Medicine Australia". mindmedicineaustralia.org.au. Retrieved 2024-03-08.
- ^ TGA https://www.tga.gov.au/sites/default/files/2023-02/notice-of-final-decision-to-amend-or-not-amend-the-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma.pdf.
{{cite web}}: Missing or empty|title=(help) - ^ "MDMA and Psilocybin are now legal in Australia. Here's what you need to know". 19 June 2023.
- ^ "An Australian doctor has just made global history. This is what happened". 7 February 2024.
- ^ "Australia the First Nation to Approve the Legal Use of MDMA and Psilocybin". Forbes.